Achieve Life Sciences Logo
US0044685008

Achieve Life Sciences

Ins Portfolio
Kostengünstig und breit gestreut in Europa investieren. Jetzt entdecken
Anzeige

Kurse werden geladen...

Prognose

Das durchschnittliche Kursziel der Analysten beträgt +4,03(+117,84%). Der Median liegt bei +4,03(+117,84%).

Kaufen
  5
Halten
  0
Verkaufen
  0

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News


  • Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters' Option to Purchase Additional Securities

    SEATTLE and VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced the closing of its underwritten public offering of 15,000,000 shares of its common stock and accompanying common warrants to purchase up to 16,766,666 shares of common stock at a public offering price of $3.00 per share and accompanying warrant, which includes common warrants to purchase up to 1,766,666 shares issued upon the partial exercise by the underwriters of their option to purchase additional shares of common stock and/or accompanying warrants. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $45.0 million.» Mehr auf globenewswire.com


  • Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering

    SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock and accompanying common warrants to purchase up to 15,000,000 shares of common stock. The shares of common stock and accompanying common warrants were offered collectively at a price to the public of $3.00 per share and accompanying common warrant. Achieve has also granted the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of common stock and/or accompanying common warrants to purchase up to an additional 2,250,000 shares of common stock (or pre-funded warrants in lieu thereof) in connection with the public offering.» Mehr auf globenewswire.com


  • Achieve Life Sciences Announces Proposed Underwritten Public Offering

    SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof). In addition, Achieve intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock and/or accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof) offered in the public offering.» Mehr auf globenewswire.com

Dividenden

Alle Kennzahlen
In 2022 hat Achieve Life Sciences +1,18 Dividende ausgeschüttet. Die letzte Dividende wurde im März 2022 gezahlt.

Unternehmenszahlen

Im letzten Quartal hatte Achieve Life Sciences einen Umsatz von 0,00 und ein Nettoeinkommen von 11,86 Mio
(EUR)März 2025
YOY
Umsatz0,00-
Bruttoeinkommen0,00100,00%
Nettoeinkommen11,86 Mio97,05%
EBITDA0,00100,00%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+64,19 Mio
Anzahl Aktien
34,69 Mio
52 Wochen-Hoch/Tief
+4,51 - +1,56
DividendenNein
Beta
1,64
KGV (PE Ratio)
1,64
KGWV (PEG Ratio)
+0,19
KBV (PB Ratio)
+7,36
KUV (PS Ratio)
0,00

Unternehmensprofil

Achieve Life Sciences, Inc. ist ein pharmazeutisches Unternehmen im klinischen Stadium, das Cytisiniclin für die Raucherentwöhnung und Nikotinsucht in Kanada, den Vereinigten Staaten und Großbritannien entwickelt und vermarktet. Das Unternehmen bietet Cytisinicline an, ein pflanzliches Alkaloid, das mit Nikotinrezeptoren im Gehirn interagiert und so die Schwere der Nikotinentzugssymptome verringert. Es hat Lizenzvereinbarungen mit Sopharma AD und der Universität von Bristol. Das Unternehmen hat seinen Sitz in Vancouver, Kanada.

Name
Achieve Life Sciences
CEO
Richard A. B. Stewart
SitzVancouver, bc
USA
Website
Industrie
Gesundheitswesen: Ausstattung und Produkte
Börsengang
Mitarbeiter25

Ticker Symbole

BörseSymbol
NASDAQ
ACHV
Frankfurt
SP4P.F
Düsseldorf
SP4P.DU
München
SP4P.MU

Assets entdecken

Shareholder von Achieve Life Sciences investieren auch in folgende Assets

🍪

Parqet nutzt Cookies.Erfahre Mehr